Clinigen declares maiden divi after impressive stock market debut

Clinigen, the speciality pharmaceuticals company which listed on the AIM market last autumn, saw shares surge on Wednesday after the firm reported a massive jump in first-half sales and declared a maiden dividend.

Clinigen, the speciality pharmaceuticals company which listed on the AIM market last autumn, saw shares surge on Wednesday after the firm reported a massive jump in first-half sales and declared a maiden dividend.

Sales soared by 86% from £32.7m to £61.0m in the six months to December 31st, while underlying profit before tax surged 54% from £6.3m to £9.7m.

Chief Executive Peter George told Sharecast that the company is "very pleased" with its trading performance in the first six months of the year after successful stock-market debut in September.

The board decided to declare the company's first interim dividend of 0.6 per share and said it is targeting progressive dividend growth.

Shares were up 11.21% at 234.65p by 11:12 on Wednesday morning, compared with the placing price of 164p.

George hailed "significant organic growth from all three operating divisions", but highlighted the standout performance of the Clinical Trial Supply (CTS) division, the dominant revenue generator of Clinigen.

CTS, which provides commercial medicines for use in clinical trials, saw an impressive 113% sales increase driven by its expansion into the US markets and new business wins. However, George did say that CTS's second half growth will likely not be as strong, though this is to expected given the "lumpiness" of seasonality in the industry.

Meanwhile, the Global Access Programs (GAP) division is on track to deliver three-fold growth this year, George said, after a whopping 222% increase in sales in the first half. GAP provides early-market access to medicines before regulatory approval or provides drugs to patients after discontinuation or withdrawal. It currently is the exclusive supplier to 32 drugs across the world.

The third division, Speciality Pharmaceuticals (SP), targets niche, hospital-only, end-of-lifecycle drugs previously owned by large pharma firms, by acquiring or in-licensing them. The company's first product is Foscavir, acquired from AstraZeneca in 2010, which achieved 22% sales growth in the first half.

Group cash and cash equivalents totalled £22.3m by the end of the half, up from just £5.2m at June 30th 2012.

Optimistic outlookThe company said that trading in the second half of the financial year has "started well".

George told Sharecast that he is confident that full-year sales would beat current market forecasts due to the strength in CTS, though expected margin reductions will likely mean that the bottom line would be in line with estimates.

He said that there is potential for good synergies between the three divisions, saying that "one plus one plus one is greater than three".

Recommended

Share tips of the week – 30 September
Share tips

Share tips of the week – 30 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Sep 2022
The best British tech stocks from a thriving sector
Share tips

The best British tech stocks from a thriving sector

Move over, Silicon Valley. Over the past two decades the UK has become one of the main global hubs for tech start-ups. Matthew Partridge explains why,…
29 Sep 2022
These 3 top value stocks offer
Share tips

These 3 top value stocks offer

Professional investor Adam Rackley of Cape Wrath Capital highlights three overlooked value stocks to buy.
29 Sep 2022
Three top-notch Asian stocks to buy
Share tips

Three top-notch Asian stocks to buy

Professional investors Adrian Lim and Pruksa Iamthongthong, managers of the Asia Dragon Trust, pick three of their favourite Asian stocks to buy now.
23 Sep 2022

Most Popular

What to do as the age of cheap money and overpriced equities ends
Investment strategy

What to do as the age of cheap money and overpriced equities ends

The age of cheap money, overpriced equities and negative interest rates is over. The great bond bull market is over. All this means you will be losin…
29 Sep 2022
Why everyone is over-reacting to the mini-Budget
Budget

Why everyone is over-reacting to the mini-Budget

Most analyses of the chancellor’s mini-Budget speech have failed to grasp its purpose and significance, says Max King
29 Sep 2022
Mini-Budget: will Kwasi Kwarteng’s gamble on growth work?
Budget

Mini-Budget: will Kwasi Kwarteng’s gamble on growth work?

The government has launched the biggest dash for growth in 50 years, relaunching an approach known as supply-side economics. What is the plan – and wi…
30 Sep 2022